X4 Pharmaceuticals (XFOR) Competitors $0.52 +0.02 (+4.01%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XFOR vs. NTGN, CDTX, AGTC, JSPR, FATE, ITOS, QURE, BTMD, LXEO, and ACBShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Neon Therapeutics (NTGN), Cidara Therapeutics (CDTX), Applied Genetic Technologies (AGTC), Jasper Therapeutics (JSPR), Fate Therapeutics (FATE), iTeos Therapeutics (ITOS), uniQure (QURE), biote (BTMD), Lexeo Therapeutics (LXEO), and Aurora Cannabis (ACB). These companies are all part of the "medical" sector. X4 Pharmaceuticals vs. Neon Therapeutics Cidara Therapeutics Applied Genetic Technologies Jasper Therapeutics Fate Therapeutics iTeos Therapeutics uniQure biote Lexeo Therapeutics Aurora Cannabis Neon Therapeutics (NASDAQ:NTGN) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking. Is NTGN or XFOR more profitable? X4 Pharmaceuticals' return on equity of -163.17% beat Neon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neon TherapeuticsN/A -199.09% -137.14% X4 Pharmaceuticals N/A -163.17%-54.32% Does the MarketBeat Community favor NTGN or XFOR? Neon Therapeutics received 96 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. Likewise, 67.87% of users gave Neon Therapeutics an outperform vote while only 66.36% of users gave X4 Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNeon TherapeuticsOutperform Votes16967.87% Underperform Votes8032.13% X4 PharmaceuticalsOutperform Votes7366.36% Underperform Votes3733.64% Does the media refer more to NTGN or XFOR? In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Neon Therapeutics. MarketBeat recorded 1 mentions for X4 Pharmaceuticals and 0 mentions for Neon Therapeutics. Neon Therapeutics' average media sentiment score of 0.00 equaled X4 Pharmaceuticals'average media sentiment score. Company Overall Sentiment Neon Therapeutics Neutral X4 Pharmaceuticals Neutral Do analysts rate NTGN or XFOR? X4 Pharmaceuticals has a consensus target price of $3.67, indicating a potential upside of 606.49%. Given X4 Pharmaceuticals' higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Neon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AX4 Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has higher earnings & valuation, NTGN or XFOR? Neon Therapeutics has higher earnings, but lower revenue than X4 Pharmaceuticals. Neon Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeon TherapeuticsN/AN/A-$79.78M-$2.86-1.07X4 Pharmaceuticals$563K155.33-$101.17M$0.086.49 Which has more risk & volatility, NTGN or XFOR? Neon Therapeutics has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Do insiders & institutionals have more ownership in NTGN or XFOR? 54.7% of Neon Therapeutics shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 38.9% of Neon Therapeutics shares are owned by company insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryX4 Pharmaceuticals beats Neon Therapeutics on 10 of the 14 factors compared between the two stocks. Ad Opportunistic TraderMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...For a limited time, he's revealing his latest forecast here. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.45M$3.15B$5.33B$8.52BDividend YieldN/A1.77%5.07%4.13%P/E Ratio6.4916.44128.4016.13Price / Sales155.33321.081,491.7792.21Price / CashN/A149.0539.5634.18Price / Book1.674.024.765.07Net Income-$101.17M-$42.25M$118.92M$225.46M7 Day Performance6.79%1.81%-0.39%0.07%1 Month Performance-18.29%8.56%6.06%3.93%1 Year Performance-30.93%35.10%38.23%32.51% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.3077 of 5 stars$0.52+4.0%$3.67+606.5%-30.9%$87.45M$563,000.006.4980News CoverageNTGNNeon TherapeuticsN/A$3.07flatN/AN/A$88.93MN/A-1.15102CDTXCidara Therapeutics4.3655 of 5 stars$12.47-1.0%$29.67+137.9%-18.5%$56.89M$53.87M-0.5090Upcoming EarningsNews CoverageAGTCApplied Genetic Technologies0.1005 of 5 stars$0.39flatN/AN/A$26.62M$320,000.00-0.2783Analyst ForecastNews CoverageJSPRJasper Therapeutics3.4255 of 5 stars$22.02+12.6%$74.86+240.0%+210.4%$331.71MN/A-4.3220FATEFate Therapeutics3.633 of 5 stars$2.87+8.3%$6.90+140.4%+25.9%$326.70M$12.32M-1.68550Short Interest ↑Gap UpITOSiTeos Therapeutics3.0375 of 5 stars$8.93+2.4%$30.50+241.5%-11.1%$326.12M$12.60M-2.9890Upcoming EarningsQUREuniQure2.2854 of 5 stars$6.68+2.3%$19.50+191.9%+1.7%$325.32M$15.84M-1.13500Upcoming EarningsBTMDbiote3.9719 of 5 stars$5.24+2.1%$8.39+60.1%-1.9%$325.07M$187.23M30.82194Short Interest ↓LXEOLexeo Therapeutics3.195 of 5 stars$9.83+3.5%$22.14+125.3%N/A$324.98M$650,000.00-0.6758Analyst ForecastNews CoverageACBAurora Cannabis0.7297 of 5 stars$5.95+0.3%N/A+22.3%$324.55M$278.98M-8.501,073Upcoming Earnings Related Companies and Tools Related Companies NTGN Competitors CDTX Competitors AGTC Competitors JSPR Competitors FATE Competitors ITOS Competitors QURE Competitors BTMD Competitors LXEO Competitors ACB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XFOR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
